Thursday 7 October 2010. The Dutch situation, Supervision and law enforcement: Josée Hansen; Clinical trials as disease mongering instruments: Trudy Dehue; Social Media and Pharma: Support or new commercial channel to care? Rob Halkes; Panel discussion and Q&A session Josée Hansen - Trudy Dehue - Rob Halkes.

Thursday 7 October 2010. Promotion to the public, European disease awareness campaigns: Teresa Alves; Promotion of prescription medicines to physicians and the public: Dee Mangin; Panel discussion and Q&A session: Teresa Alves - Dee Mangin.

Thursday 7 October 2010. The influence on rational use of medicine: Kees de Joncheere; The influence on patients: Ilaria Passarani; Redesigning the incentives for the pharmaceutical industry: Dean Baker; Panel discussion and Q&A session: Kees de Joncheere - Ilaria Passarani - Dean Baker.

Friday 8 October 2010. Financial and insurance aspects: Henk Eleveld; Independent information for patients: Hilda Bastian; Panel discussion and Q&A session Henk Eleveld - Hilda Bastian.

Friday 8 October 2010. Self regulation on disease promotion: Lode Wigersma; Regulation of pharmaceutical promotion: Graham Dukes; Guidelines and HTA: Meindert Boysen. Panel discussion and Q&A session Lode Wigersma - Graham Dukes - Meindert Boysen.

Friday 8 October 2010. The industry: partner in solutions?: Michel Dutrée; Should the Medicines Evaluation Board be involved?: Bert Leufkens; International Cooperation: Peter Mansfield; Final panel discussion: towards a joint statement Michel Dutrée - Bert Leufkens - Peter Mansfield. Closing remarks: Ruud Coolen van Brakel.